Atea Pharmaceuticals, Inc. (AVIR) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen. Welcome to Atea Pharmaceuticals' second quarter 2021 financial results conference call. At this time, all participants are in listen-only mode. Following the formal remarks, we will open up for your questions. I would now like to turn the call over to Jonay Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Please proceed. Thank you, Operator. Good afternoon, everyone, and welcome to Attea Pharmaceutical's second quarter 2021 financial results conference call. This afternoon, we issued a press release which outlines the topics that we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at ir.atteafarma.com. With me today from Attea are founder, chairman, and chief executive officer, Dr. John Pierre Somadosi, Chief Development Officer, Dr. Jim Hammond, Chief Financial Officer, Executive Vice President of Legal, Andrea Corcoran, and our Chief Commercial Officer, John Vavrica. They will all be available for the Q&A portion of today's call. On the call today, we have a lot of important content to review. John here will provide an overview on the current COVID-19 environment and AT527's potential to address these key challenges. Janet will review our clinical progress and results. for AT527 for the treatment of COVID and discuss AT752 for the treatment of dengue fever. John will then provide an overview of the U.S. commercial opportunities for AT527. Andrea will provide a financial update. And John Pierre will provide closing remarks. Before we begin the call, I would like to remind you that today's discussion will contain forward-looking statements that involve risk and securities. T...